Trial · NCT06548100
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events (TEAEs) | Up to week 68 | |
| Primary | Severity of TEAEs | Up to week 68 | |
| Secondary | Change in Hemoglobin A1c (HbA1c) | Baseline, week 20 and week 52 | |
| Secondary | Occurrence of HbA1c <7% | Week 20 and week 52 | |
| Secondary | Occurrence of HbA1c <6.5% | Week 20 and week 52 | |
| Secondary | Occurrence of requiring therapy with insulin in participants treated with mibavademab | Week 20 and week 52 | |
| Secondary | Change in total insulin dose | Baseline, week 20 and week 52 | |
| Secondary | Change in fasting plasma glucose | Baseline, week 20 and week 52 | |
| Secondary | Percent change in fasting triglycerides | Baseline, week 20 and week 52 | |
| Secondary | Occurrence of fasting triglycerides <500 mg/dL in participants treated with mibavademab | Baseline, week 20 and week 52 | |
| Secondary | Occurrence of fasting triglycerides <200 mg/dL in participants treated with mibavademab | Baseline, week 20 and week 52 | |
| Secondary | Occurrence of fasting triglycerides <150 mg/dL in participants treated with mibavademab | Baseline, week 20 and week 52 | |
| Secondary | Concentrations of total mibavademab in serum | Up to week 68 | |
| Secondary | Incidence of anti-drug antibodies (ADAs) to mibavademab | Up to week 68 | |
| Secondary | Titer of ADAs to mibavademab | Up to week 68 | |
| Secondary | Incidence of neutralizing antibodies (Nabs) to mibavademab | Up to week 68 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06548100/registered